Amneal Pharmaceuticals (AMRX) announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and Drug Administration (FDA) its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults. Second, Amneal has received approval from the FDA for exenatide, which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1) agonist and reflects its innovation capabilities in peptide development and drug-device combinations.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler
- Amneal Pharmaceuticals Reports Q3 2024 Financial Results
- Amneal Pharmaceuticals reports Q3 adjusted EPS 16c, consensus 13c
- Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c
- AMRX Earnings this Week: How Will it Perform?